Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2013

01-03-2013 | Original Paper

The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome

Authors: Ming Wu, Ding-yang Liu, Xian-rui Yuan, Qing Liu, Xin-jun Jiang, Dun Yuan, Jun Huang, Xue-jun Li, Zhi-quan Yang

Published in: Medical Oncology | Issue 1/2013

Login to get access

Abstract

Moesin, a member of the ERM family, acts as a linker between the actin cytoskeleton and the plasma membrane and plays a key role in the control of cell morphology, motility, adhesion and other processes of tumourigenesis. The expression pattern and clinical significance of moesin in astrocytoma remain unknown. In this study, we used RT-PCR to systematically investigate the expression of moesin in 49 astrocytomas of different pathological grade and 6 normal brain tissues. We found that the mRNA expression levels of moesin in astrocytomas were significantly higher in comparison with normal brain tissues. Furthermore, moesin up-regulation was correlated with pathological grade of astrocytomas. Subsequently, we tested 112 astrocytomas and 14 normal brain tissues by immunohistochemistry. Similar results were also confirmed. Univariate and multivariate survival analysis were used to determine the correlations of moesin expression with overall survival and progression-free survival. Our results showed the expression of moesin was strongly negatively correlated with the patient progression-free survival and overall survival. These results suggest moesin protein involved in the genesis and progression of astrocytomas and might be regarded as an independent predictor of poor prognosis.
Literature
1.
Lefranc F, Rynkowski M, DeWitte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3–35.PubMedCrossRef
2.
Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108(9):3749–54.PubMedCrossRef
3.
Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL, Wang K, et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus. 2011;30(5):E7.PubMed
4.
Tsukita S, Yonemura S. ERM proteins: head-to-tail regulation of actin-plasma membrane interaction. Trends Biochem Sci. 1997;22(2):53–8.PubMedCrossRef
5.
Speck O, Hughes SC, Noren NK, Kulikauskas RM, Fehon RG. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature. 2003;421(6918):83–7.PubMedCrossRef
6.
Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.PubMedCrossRef
7.
Hua D, Ding D, Han X, Zhang W, Zhao N, Foltz G, et al. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Oncol Rep. 2012;27(3):700–6.PubMed
8.
Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182–6.PubMedCrossRef
9.
Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein six-1 as key metastatic regulators. Nat Med. 2004;10(2):175–81.PubMedCrossRef
10.
Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005;7(3):R365–73.PubMedCrossRef
11.
Okamura D, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, et al. Ezrin expression is associated with hepatocellular carcinoma possibly derived from progenitor cells and early recurrence after surgical resection. Mod Pathol. 2008;21(7):847–55.PubMedCrossRef
12.
Carmeci C, Thompson DA, Kuang WW, Lightdale N, Furthmayr H, Weigel RJ. Moesin expression is associated with the estrogen receptor-negative breast cancer phenotype. Surgery. 1998;124(2):211–7.PubMedCrossRef
13.
Charafe-Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121(8):1779–85.PubMedCrossRef
14.
Cui Y, Wu J, Zong M, Song G, Jia Q, Jiang J, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009;124(7):1614–21.PubMedCrossRef
15.
Estecha A, Sanchez-Martin L, Puig-Kroger A, Bartolome RA, Teixido J, Samaniego R, et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.PubMedCrossRef
16.
Li YJ, Tao XF, He Y, Fu H. Expression of ezrin, moesin in the gastric carcinoma and its clinical significance. Chin J Cancer. 2007;16:550–2.
17.
Ou-Yang M, Liu HR, Zhang Y, Zhu X, Yang Q. ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells. Biochimie. 2011;93(5):954–61.PubMedCrossRef
18.
Morales FC, Molina JR, Hayashi Y, Georgescu MM. Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol. 2010;12(6):528–39.PubMedCrossRef
19.
Osawa H, Smith CA, Ra YS, Kongkham P, Rutka JT. The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells. Neuro Oncol. 2009;11(4):381–93.PubMedCrossRef
20.
Tynninen O, Carpen O, Jaaskelainen J, Paavonen T, Paetau A. Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol. 2004;30(5):472–7.PubMedCrossRef
21.
Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011;104(3):639–46.PubMedCrossRef
22.
Nabors LB. Targeted molecular therapy for malignant gliomas. Curr Treat Options Oncol. 2004;5(6):519–26.PubMedCrossRef
23.
Neisch AL, Speck O, Stronach B, Fehon RG. Rho1 regulates apoptosis via activation of the JNK signaling pathway at the plasma membrane. J Cell Biol. 2010;189(2):311–23.PubMedCrossRef
24.
Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, et al. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.PubMed
25.
Ichikawa T, Masumoto J, Kaneko M, Saida T, Sagara J, Taniguchi S. Expression of moesin and its associated molecule CD44 in epithelial skin tumors. J Cutan Pathol. 1998;25(5):237–43.PubMedCrossRef
26.
Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics. 2006;7:268.PubMedCrossRef
Metadata
Title
The expression of moesin in astrocytoma: correlation with pathologic grade and poor clinical outcome
Authors
Ming Wu
Ding-yang Liu
Xian-rui Yuan
Qing Liu
Xin-jun Jiang
Dun Yuan
Jun Huang
Xue-jun Li
Zhi-quan Yang
Publication date
01-03-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0372-z

Other articles of this Issue 1/2013

Medical Oncology 1/2013 Go to the issue

Original Paper

Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo

Original Paper

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

Letter to the Editor

Acute promyelocytic leukemia with t(15;17) and two previously unreported additional cytogenetic abnormalities

Original Paper

The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma

Original Paper

Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer

Original Paper

Investigation on MDR1 gene polymorphisms and its relationship with breast cancer risk factors in Chinese women

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits